Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast

Breast Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04767594 2026-04-13

PERFORM

Active not recruiting

1,407 enrolled

Breast

Breast Neoplasms

NCT03820830 2026-04-09

POLAR

Phase 3 Active not recruiting

405 enrolled

Breast

Breast Cancer Recurrent

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

96 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT05399329 2026-04-09

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Completed

693 enrolled

Breast

Breast Neoplasms

NCT06188520 2026-04-08

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06962969 2026-04-02

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Completed

1 enrolled

Breast

Breast Neoplasms

NCT04654208 2026-03-31

SIRI

Recruiting

1,500 enrolled

Breast

Breast Neoplasms

NCT07493291 2026-03-30

PALLAS-IRAQ

Active not recruiting

100 enrolled

Breast

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07347600 2026-03-20

reaINAVO

Recruiting

500 enrolled

Breast

Breast Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

33 enrolled

Breast

Breast Neoplasms

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

500 enrolled

Breast

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 3 FDA

Breast

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast

Breast Neoplasms

NCT04862663 2026-03-12

CAPItello-292

Phase 3 Recruiting

895 enrolled

Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

200 enrolled

Breast

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

720 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02